Obesity (defined as a body mass index (BMI) >30kg/m2) is a chronic disease that is increasing in prevalence in adults, adolescents, and children and is now considered to be a global epidemic. The National Health and Nutrition Examination Survey (NHANES) in 2016 showed the prevalence of obesity in the United States to be 39.6% (37.9% in men and 41.1% of women), up from 22.9% in 1994.
At Texas Diabetes and Endocrinology we investigate many aspects of this disease. We rule out any possible secondary causes (such as pituitary, thyroid, adrenal or ovarian abnormalities) as clinically indicated, discuss contributing medications, and obtain a thorough weight gain/weight loss history. Obesity is associated with a significant increase in morbidity (including diabetes mellitus, hypertension, dyslipidemia, heart disease, stroke, sleep apnea, and cancer) and we assess these and come up with a comprehensive plan to manage them.
Weight loss itself is associated with a reduction in obesity-associated morbidity and we are committed to helping our patients achieve these benefits. We counsel all patients on lifestyle and behavioral modification. We also offer medically supervised programs to assist with individual goals. Muscle Wise is one program we utilize: it provides structure and one-on-one coaching that can help achieve not only weight loss but also reduction in comorbidities and often medications. We also use FDA-approved weight loss medications as needed to help our patients achieve their goals.
Finally we conduct clinical trials at all of our locations and these often involve obesity treatments. Currently at the south office we are conducting a study on a medication (semaglutide) to evaluate weight loss and long-term cardiovascular outcomes.
Posted on July 31, 2020
Posted on July 30, 2020